Spinal Cord Stimulator Complications: What Attorneys Need to Know About Implant Malpractice Litigation
Spinal cord stimulation (SCS) has become one of the most widely used interventional treatments for chronic neuropathic pain, failed back surgery syndrome, and complex regional pain syndrome. It is also one of the most frequently litigated procedures in pain medicine, because the implant is a permanent hardware device placed near the spinal cord, and the standard of care governs not just the surgical technique but the entire arc of patient selection, trial period, implantation, and long-term device management. Attorneys who encounter an SCS complication case are typically evaluating one of several recurring failure points, each of which requires a pain medicine or neurosurgical expert who implants these devices in active practice.
How SCS Litigation Differs From Other Interventional Pain Cases
Unlike a single injection or nerve block, SCS therapy unfolds in stages — patient selection and psychological screening, a percutaneous trial period, and, if the trial is successful, permanent implantation of leads and an implantable pulse generator (IPG). Because the standard of care applies at each stage independently, a case can turn on a failure that occurred weeks or months before the injury that ultimately brought the patient to an attorney. A poorly selected candidate who should never have proceeded to permanent implant, a trial that was called "successful" without adequate documentation of percent pain relief, and a technically competent implant in an inappropriate patient can all produce the same bad outcome — but each represents a different point of deviation that the expert record review must isolate.
The Most Common Liability Theories in SCS Cases
Inadequate patient selection and screening. Professional society guidelines call for a structured multidisciplinary evaluation before a patient proceeds to an SCS trial, including psychological screening to rule out untreated depression, active substance use disorder, or unrealistic expectations that predict poor outcomes. A provider who skips or abbreviates this screening — particularly in a patient with a documented psychiatric history — may be deviating from the accepted standard, and a subsequent poor outcome or complication becomes harder to defend when the screening step was never properly performed.
Trial period documentation failures. The percutaneous trial is meant to be an objective gate: professional guidelines generally expect at least 50 percent reported pain relief, sustained over a meaningful trial period, before proceeding to permanent implantation. Charts that show a permanent implant scheduled without a documented pain diary, without a specific percentage of relief recorded, or based solely on the patient's verbal report at a single follow-up visit reflect a documentation gap that experts frequently flag as a standard-of-care departure, especially when the permanent device subsequently fails to relieve the patient's pain at all.
Lead migration and hardware failure. Leads can migrate from their intended epidural position due to inadequate anchoring, patient movement, or anchor failure, producing loss of paresthesia coverage or stimulation in unintended areas. Fracture of the lead or its extension wire, IPG malfunction, and battery failure are also recognized device complications. The critical liability question is not whether migration or hardware failure occurred — these are known risks disclosed in informed consent — but whether the post-implant follow-up protocol was adequate to detect the failure promptly, and whether the anchoring technique used at implant met the accepted standard.
Infection and epidural hematoma. As with any implanted hardware, SCS trials and implants carry infection risk, and permanent implants carry the more serious risk of epidural abscess if infection tracks along the lead. Deep surgical site infections that are not recognized and treated promptly can progress to spinal cord compression. Epidural hematoma, though rare, is a recognized complication particularly in patients on anticoagulation, and the standard of care requires appropriate anticoagulation management and holding periods before both the trial and implant procedures. A delay in recognizing post-procedural neurological changes consistent with hematoma or abscess — new-onset weakness, worsening back pain, fever, or bowel or bladder dysfunction — is one of the most serious and most litigated failure points in SCS practice.
Neurological injury from lead placement. Direct spinal cord or nerve root injury during percutaneous or paddle lead placement, while uncommon, can result in permanent deficit. These cases require careful analysis of the fluoroscopic images obtained during placement, the reported patient feedback during an awake trial procedure, and whether the implanting physician responded appropriately to any intraoperative report of pain, paresthesia in an unexpected distribution, or motor response.
Standard of Care and Documentation
The standard of care in SCS practice is informed by guidelines from pain medicine and neuromodulation societies, device manufacturer implantation protocols, and published consensus statements on patient selection and trial evaluation. Attorneys evaluating these cases should request the complete record across every stage of care: the psychological evaluation, the trial period pain diaries and follow-up notes, informed consent documentation specific to the permanent implant, operative and fluoroscopic records from both the trial and implant procedures, post-operative nursing and follow-up notes, and any device interrogation data showing impedance readings or programming history that can help establish when a hardware failure began.
Causation Analysis in SCS Cases
Causation in SCS litigation frequently depends on temporal correlation between a documented event — a fall, a specific movement, a period of missed follow-up — and the onset of loss of stimulation coverage or new neurological symptoms. Device interrogation records, which log impedance and usage data, can sometimes pinpoint the timing of a lead fracture or migration with more precision than clinical documentation alone, and a pain medicine expert experienced in reading this data is often essential to building a defensible causation timeline. In infection and hematoma cases, causation analysis instead centers on the interval between symptom onset and diagnostic workup, correlated against known progression rates for epidural infection and compressive injury.
Selecting a Pain Medicine Expert for SCS Cases
The ideal expert for an SCS case is a board-certified pain medicine physician or neurosurgeon who currently performs SCS trials and implants, is familiar with the major device platforms in use, and can speak credibly to both the procedural technique and the patient selection process that preceded it. Attorneys should confirm that a prospective expert has hands-on implant experience rather than only a general pain management background, since the technical and device-specific issues in these cases — anchoring technique, lead type, programming — require specialized familiarity.
How ApexMedLaw Approaches SCS Cases
ApexMedLaw's pain medicine panel includes physicians who implant spinal cord stimulators in active practice and are fluent in the patient selection guidelines, trial documentation standards, and device-specific complication profiles that these cases require. Our experts review the full continuum of care — from psychological screening through trial, implant, and post-operative follow-up — to identify the specific point of deviation and build a causation narrative supported by device interrogation data where available.
We provide detailed medical record review, written expert reports, deposition preparation, and trial testimony for both plaintiff and defense counsel. Contact ApexMedLaw to discuss your spinal cord stimulator or neuromodulation malpractice case.
This post is for informational purposes and does not constitute legal advice. Standards vary by jurisdiction.